Paris - Delayed Quote EUR

OSE Immunotherapeutics SA (OSE.PA)

Compare
7.06 +0.05 (+0.71%)
At close: 2:00:22 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for OSE.PA

Recent News: OSE.PA

View More
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO
GlobeNewswire 6 days ago
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®
GlobeNewswire 13 days ago
OSE Immunotherapeutics Strengthens Leadership and Executive Committee

OSE Immunotherapeutics Strengthens Leadership and Executive Committee
GlobeNewswire 22 days ago
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
GlobeNewswire last month
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
GlobeNewswire 2 months ago
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
GlobeNewswire 2 months ago
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
GlobeNewswire 3 months ago
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis
GlobeNewswire 4 months ago
Boehringer and OSE to advance cancer immunotherapy to clinics

Boehringer and OSE to advance cancer immunotherapy to clinics
Pharmaceutical Technology 5 months ago
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
GlobeNewswire 5 months ago
OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
GlobeNewswire 5 months ago
View More

Related Tickers

ADOC.PA Adocia SA
5.98
+1.01%
 
ALCOX.PA Nicox S.A.
0.2830
-2.41%
 
ALVAL.PA Valbiotis SA
1.3860
+1.17%
 
TNG.PA Transgene SA
0.6950
-0.71%
 
DBV.PA DBV Technologies S.A.
0.6190
-1.28%
 
ALSEN.PA Sensorion SA
0.6160
-0.32%
 
NURPF Neuren Pharmaceuticals Limited
7.87
0.00%
 
VICO.ST Vicore Pharma Holding AB (publ)
7.71
-1.91%
 
ALTME.PA TME Pharma N.V.
0.0775
+3.89%
 
ULTI.OL Ultimovacs ASA
2.4450
-4.12%